Nurix Therapeutics (NRIX) said Wednesday it received PRIME designation from the European Medicines Agency for NX-5948 to treat adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The PRIME, or priority medicines, designation follows "encouraging" safety and efficacy data from an ongoing phase 1 trial, the company said.
To be eligible for PRIME, medicines must target an unmet medical need and show potential benefit for patients based on early clinical data, the firm said.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。